BR112018076015A2 - formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . - Google Patents
formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .Info
- Publication number
- BR112018076015A2 BR112018076015A2 BR112018076015-3A BR112018076015A BR112018076015A2 BR 112018076015 A2 BR112018076015 A2 BR 112018076015A2 BR 112018076015 A BR112018076015 A BR 112018076015A BR 112018076015 A2 BR112018076015 A2 BR 112018076015A2
- Authority
- BR
- Brazil
- Prior art keywords
- polyacrylic acid
- acid polymer
- linear
- immunogenic formulations
- immunogens
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 229920002125 Sokalan® Polymers 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282465 Canis Species 0.000 abstract 1
- 241000283707 Capra Species 0.000 abstract 1
- 241000283086 Equidae Species 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000013613 expression plasmid Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F6/00—Post-polymerisation treatments
- C08F6/001—Removal of residual monomers by physical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/04—Acids; Metal salts or ammonium salts thereof
- C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção fornece novas formulações imunológicas e vacinas compreendendo um adjuvante de polímero de ácido poliacrílico não reticulado, recentemente aplicado. os adjuvantes podem ser combinados com uma grande variedade de imunógenos para produzir vacinas que são seguras e eficazes quando administradas a uma vasta gama de animais alvo. os imunógenos podem incluir, mas não estão limitados a: patógenos inativados, patógenos atenuados, subunidades, vetores de expressão recombinantes, plasmídeos ou combinações dos mesmos. os animais podem incluir, mas não estão limitados a: humanos, murinos, caninos, felinos, equinos, suínos, ovinos, caprinos e bovinos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351492P | 2016-06-17 | 2016-06-17 | |
US62/351,492 | 2016-06-17 | ||
US2017218819 | 2017-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018076015A2 true BR112018076015A2 (pt) | 2019-03-26 |
BR112018076015A8 BR112018076015A8 (pt) | 2022-06-28 |
Family
ID=59295306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018076015A BR112018076015A8 (pt) | 2016-06-17 | 2017-06-15 | Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . |
Country Status (10)
Country | Link |
---|---|
US (1) | US11554170B2 (pt) |
EP (1) | EP3471760A1 (pt) |
JP (1) | JP7018941B2 (pt) |
KR (1) | KR20190044052A (pt) |
CN (1) | CN109475615B (pt) |
AU (1) | AU2017286727B2 (pt) |
BR (1) | BR112018076015A8 (pt) |
CA (1) | CA3027877A1 (pt) |
MX (1) | MX2018015787A (pt) |
WO (1) | WO2017218819A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11524069B2 (en) * | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
CA3095174A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
WO2019195284A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic influenza-ferritin polypeptides |
KR20210018206A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 호흡기 세포융합 바이러스 폴리펩타이드 |
JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイSanofi | フェリチンタンパク質 |
WO2019195314A2 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic epstein barr virus polypeptides |
CN109134724A (zh) * | 2018-07-24 | 2019-01-04 | 石家庄哈顿生物技术有限公司 | 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法 |
CN113924111A (zh) * | 2019-01-04 | 2022-01-11 | 勃林格殷格翰动物保健美国公司 | 减毒的支气管败血性博德特菌菌株、包含该减毒的菌株的口服疫苗及其制备和使用方法 |
CN114957407A (zh) | 2019-04-02 | 2022-08-30 | 赛诺菲 | 抗原性多聚呼吸道合胞病毒多肽 |
CN113444743A (zh) * | 2021-06-22 | 2021-09-28 | 贵州大学 | 含佐剂基因的羊支原体肺炎二价核酸疫苗的构建方法 |
WO2023120535A1 (ja) * | 2021-12-20 | 2023-06-29 | 東興薬品工業株式会社 | ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3790665A (en) | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
US3919411A (en) | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
NZ215069A (en) * | 1985-03-01 | 1988-06-30 | Reckitt & Colmann Prod Ltd | Pharmaceutical composition with histamine h 2 -receptor antagonist |
AU641121B2 (en) | 1988-01-29 | 1993-09-16 | Chiron Corporation | Recombinant CMV neutralizing proteins |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5846805A (en) | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
SK98695A3 (en) | 1993-02-08 | 1996-11-06 | Bayer Ag | Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines |
FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
BE1008977A5 (fr) * | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
US5866401A (en) | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
MXPA06000942A (es) | 2003-07-24 | 2006-03-30 | Merial Ltd | Nuevas formulaciones de vacunas. |
GB0400264D0 (en) | 2004-01-07 | 2004-02-11 | Polytherics Ltd | Complexes |
US7425336B2 (en) | 2005-08-25 | 2008-09-16 | Mevial Limited | Canine influenza vaccines |
GB0805356D0 (en) | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
WO2011100665A2 (en) * | 2010-02-12 | 2011-08-18 | Rhodia Operations | Rheology modifier compositions and methods of use |
US20150044242A1 (en) * | 2012-03-12 | 2015-02-12 | Advanced Bioadjuvants Llc | Adjuvant and Vaccine Compositions |
-
2017
- 2017-06-15 AU AU2017286727A patent/AU2017286727B2/en active Active
- 2017-06-15 KR KR1020197001525A patent/KR20190044052A/ko not_active IP Right Cessation
- 2017-06-15 US US15/624,405 patent/US11554170B2/en active Active
- 2017-06-15 MX MX2018015787A patent/MX2018015787A/es unknown
- 2017-06-15 WO PCT/US2017/037745 patent/WO2017218819A1/en unknown
- 2017-06-15 EP EP17736804.0A patent/EP3471760A1/en active Pending
- 2017-06-15 CN CN201780044245.6A patent/CN109475615B/zh active Active
- 2017-06-15 BR BR112018076015A patent/BR112018076015A8/pt unknown
- 2017-06-15 CA CA3027877A patent/CA3027877A1/en active Pending
- 2017-06-15 JP JP2019518171A patent/JP7018941B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CA3027877A1 (en) | 2017-12-21 |
WO2017218819A1 (en) | 2017-12-21 |
KR20190044052A (ko) | 2019-04-29 |
MX2018015787A (es) | 2019-04-22 |
JP2019524873A (ja) | 2019-09-05 |
US20170360923A1 (en) | 2017-12-21 |
CN109475615B (zh) | 2023-04-07 |
US11554170B2 (en) | 2023-01-17 |
AU2017286727A1 (en) | 2019-01-31 |
CN109475615A (zh) | 2019-03-15 |
AU2017286727B2 (en) | 2024-02-08 |
BR112018076015A8 (pt) | 2022-06-28 |
EP3471760A1 (en) | 2019-04-24 |
JP7018941B2 (ja) | 2022-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018076015A2 (pt) | formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . | |
BR112017005833A2 (pt) | vacinas recombinantes fmdv e seus usos | |
CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
BR112012023046A2 (pt) | vacinas de vírus de febre aftosa recombinantes e seus respectivos usos | |
BR112018013369A2 (pt) | compostos depsipeptídicos anti-helmínticos | |
CY1124218T1 (el) | Ανασυνδυασμενοι αδενοϊικοi φορεις εμβολιων fmdv και χρησεις αυτων | |
MX2017005721A (es) | Composicion veterinaria masticable agradable al paladar. | |
BR112016006326A2 (pt) | formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina | |
BR112018003967A2 (pt) | tratamento de hipersensibilidade à picada de inseto | |
EA201791910A1 (ru) | Инъецируемые препараты длительного действия, содержащие изоксазолиновое действующее вещество, способы и применение | |
BR112018070634A2 (pt) | vacina universal para doenças virais | |
BR112015009541A2 (pt) | novos adjuvantes de mucosa e sistemas de aplicação | |
BR112017011838A2 (pt) | polímeros de ligação a prótons para administração oral | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
UA110328C2 (en) | Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration | |
CY1124640T1 (el) | Μια meθοδος αντιμετωπισης μυκητιασικων μολυνσεων | |
BR112018071121A2 (pt) | dispositivo de injeção energizados para fornecer formulações de múltiplos líquidos, incluindo vacinas | |
MX2020009639A (es) | Vacunas de peptídos contra interleucina-31. | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
BR112018008840A8 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112014020025A8 (pt) | Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
BR112018010494A8 (pt) | proteínas de fusão fmdv e e2 e seus usos | |
CY1121773T1 (el) | Χρηση του παλμιτοϋλοαιθανολαμιδιου σε συνδυασμο με οπιοειδη | |
EA201892003A1 (ru) | Лечение атопического дерматита собак | |
BR112019008720A2 (pt) | polinucleotídeo isolado, polinucleotídeo de cdna, polinucleotídeo infeccioso, composição, composição farmacêutica, vetor de pestivírus porcino, pestivírus quimérico, vacina para animais, kit, métodos para proteger um leitão contra uma doença associada com pestivírus, detectar pestivírus, detectar antígeno de pestivírus, preparar uma vacina e controlar uma infecção com um pestivírus em animais, e, ensaio diagnóstico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: SANOFI PASTEUR (FR) ; MERIAL, INC. (US) |
|
B25A | Requested transfer of rights approved |
Owner name: SANOFI PASTEUR (FR) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US) |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |